@article{article_1758111, title={Clinical course and safety of hyperbaric oxygen therapy in patients with hematologic malignancies: a retrospective analysis}, journal={Journal of Medicine and Palliative Care}, volume={6}, pages={458–464}, year={2025}, DOI={10.47582/jompac.1758111}, author={Canarslan Demir, Kübra and Avcı, Ahmet Uğur and Özgök Kangal, Kübra and Ceylan, Berrin and Abaylı, Selcen Yüsra and Yılmaz, Kerim Bora}, keywords={Hyperbaric oxygenation, hematologic neoplasms, supportive care, immunosuppression, wound healing}, abstract={Aims: Given the high risk of treatment-related complications such as hemorrhagic cystitis (HC), avascular necrosis (AVN), and impaired wound healing in patients with hematologic malignancies undergoing intensive therapies, this study aims to evaluate the safety and clinical effectiveness of hyperbaric oxygen therapy (HBOT) as a supportive treatment modality in this vulnerable patient population. Methods: This retrospective cohort study evaluated 20 patients with hematologic malignancies who received HBOT at a tertiary hyperbaric medicine center between 2017 and 2023. Demographic data, HBOT indications, complications, outcomes, and mortality were analyzed. HBOT was administered at 2.4 ATA in either monoplace or multiplace chambers. Results: HBOT indications included AVN (35%), HC (30%), impaired wound healing (25%), sudden sensorineural hearing loss (5%), and central retinal artery occlusion (5%). Median follow-up was 595 days. No serious HBOT-related complications were reported except for a single case of mild barotrauma. No statistically significant association was found between the number of HBOT sessions and mortality or recurrence. Improvements in clinical outcomes were observed in most patients with HC and wound healing problems. Conclusion: HBOT appears to be a feasible and well-tolerated supportive treatment in patients with hematologic malignancies, particularly when administered under strict infection control measures. These findings support further prospective studies to validate its safety and efficacy in this vulnerable population.}, number={5}, publisher={MediHealth Academy Yayıncılık}